Traveling Exhibit of Cancer Educational Resources

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE) has joined with its first partner, the American Association for Cancer Education (AACE), to put together an international traveling exhibit of educational materials and resources for cancer education, to be shown at many of the smaller cancer congresses around the world, Charles D. Sherman, Jr., MD, told Oncology News International.

ROCHESTER, NY--The WHO International Network for Cancer Education (INCE)has joined with its first partner, the American Association for CancerEducation (AACE), to put together an international traveling exhibit ofeducational materials and resources for cancer education, to be shown atmany of the smaller cancer congresses around the world, Charles D. Sherman,Jr., MD, told Oncology News International.

Dr. Sherman is director of the Highland Hospital Cancer Treatment Center,Rochester, NY, and co-director of INCE, along with Richard R. Love, MD,of the University of Wisconsin, Madison.

The INCE expects the initial collection to be exhibited at the AACEmeeting in Atlanta next October; it then will be reviewed and refined fordisplay elsewhere. An offshoot of this project is the production of anInternational Directory of materials and resources for cancer education,as well as individuals and organizations involved in cancer education.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content